Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia

Trial Details

NCT ID

NCT06793241

Phase

EARLY_PHASE1

Sponsor

Zhejiang University

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells injection

Locations (sample)

• Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

• 1\. Age ≥18 years old, gender unlimited;
• 2\. Abnormal B cell immunotyping was CD19 positive;
• 3\. Patients diagnosed with B-cell acute lymphoblastic leukemia by histological or immunotyping;
• 4\. Meets the diagnosis of relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and includes any of the following conditions:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.